Access cutting-edge triple-negative breast cancer treatment through this clinical trial at a research site in Hot Springs. Study-provided care at no cost to qualified participants.
Access triple-negative breast cancer specialists in Hot Springs at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple-negative breast cancer treatment provided free
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates
Sponsor: Bristol-Myers Squibb
Check if you qualify for this triple-negative breast cancer clinical trial in Hot Springs, AR
If you're searching for triple-negative breast cancer treatment options in Hot Springs, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hot Springs research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple-negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.